

# BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 11<sup>th</sup> February, 2025

To, The Secretary ( <b>DCS/Compliance</b> ), Corporate Relationship Department, <b>BSE Limited (DCS/Compliance)</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary ( <b>Listing/Compliance</b> ), <b>National Stock Exchange of India Limited</b> , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai - 400051
---	--

**Subject: Integrated Filing (Financial) for the quarter and nine-months ended 31<sup>st</sup> December, 2024.**

**Reference: Biofil Chemicals and Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)**

Dear Sir/Madam,

In accordance with amendments to the SEBI (Listing Obligations and Disclosure Requirements) (Third Amendment) Regulations, 2024 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, we are enclosing herewith the Integrated Filing (Financial) for the quarter and nine-months ended 31st December, 2024 for your reference and records.

The above information will also be available on the website of the Company at [www.biofilgroup.net](http://www.biofilgroup.net).

You are requested to take on record the above said information for your reference and records.

Thanking you,

Yours Faithfully

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

**RAMESH SHAH  
CHAIRMAN & MANAGING DIRECTOR  
DIN: 00028819**

Enclosed: As above

ANNEXURE A- FINANCIAL RESULTS FOR THE QUARTER AND NINE-MONTHS ENDED 31ST DECEMBER, 2024. (attach Full results with limited review and segment if any as filed with exchange )

ANNEXURE B STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC :- **NOT APPLICABLE**

ANNEXURE C: FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES –

<b>S. No</b>	<b>Particulars</b>	<b>In INR Crore</b>
<b>1.</b>	<b>Loans/ revolving facilities like cash credit from banks/ financial institutions</b>	0.00
A.	Total amount outstanding as on date	0.00
B.	Of the total amount outstanding, amount of default as on date	0.00
<b>2.</b>	<b>Unlisted debt securities i.e. NCDs and NCRPS</b>	0.00
A.	Total amount outstanding as on date	0.00
B.	Of the total amount outstanding, amount of default as on date	0.00
<b>3.</b>	<b>Total financial indebtedness of the listed entity including short term and long-term debt</b>	0.00

ANNEXURE D: FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (APPLICABLE ONLY FOR HALF-YEARLY FILINGS I.E., 2ND AND 4TH QUARTER) :- **NOT APPLICABLE FOR THIS QUARTER**

ANNEXURE E: STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (STANDALONE AND CONSOLIDATED SEPARATELY) (APPLICABLE ONLY FOR ANNUAL FILING I.E., 4TH QUARTER):- **NOT APPLICABLE FOR THIS QUARTER**

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED**

**RAMESH SHAH**  
**CHAIRMAN & MANAGING DIRECTOR**  
**DIN: 00028819**



<b>XVII</b>	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	<b>16.46</b>	<b>2.43</b>	<b>9.33</b>	<b>35.81</b>	<b>46.05</b>	<b>90.13</b>
<b>XVIII</b>	<b>Paid-Up equity share capital (face value of Rs 10/- each)</b>	1627.38	<b>1627.38</b>	1627.38	1627.38	1627.38	<b>1627.38</b>
<b>XIX</b>	<b>Reserves (Excluding Revaluation Reserve)</b>						(183.30)
<b>XX</b>	<b>Earnings per equity shares (for continuing operation):</b>						
	(1) Basic (Rs)	0.10	0.01	0.06	0.22	0.28	0.44
	(2) Diluted (Rs)	0.10	0.01	0.06	0.22	0.28	0.44
<b>XXI</b>	<b>Earnings Per Equity Share (for discontinued operation)</b>						
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
<b>XXII</b>	<b>Earnings Per Equity Share (for continuing &amp; discontinued operation)</b>						
	(1) Basic (Rs)	0.10	0.01	0.06	0.22	0.28	0.44
	(2) Diluted (Rs)	0.10	0.01	0.06	0.22	0.28	0.44

1 The above unaudited financial results for the Quarter and nine month ended December 31, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on February 11, 2025. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.

2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments  
a. Pharma Division  
b. Chemicals Division.

4 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.

5 The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors.

Date: 11th February, 2025

Place : Indore

**FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.**

Ramesh Shah  
Digitally signed  
by Ramesh Shah  
Date: 2025.02.11  
17:16:18 +05'30'

**RAMESH SHAH**  
**CHAIRMAN & MANAGING DIRECTOR**  
**( DIN: 00028819 )**



Segment wise Revenue, Results and Capital Employed for quarter ended and nine month ended 31st December 2024

( Amount in Lakhs)

S.No.	Particulars	QUARTER ENDED			NINE MONTH ENDED		Year Ended
		3 months ended on 31/12/2024	Previous 3 months ended on 30/09/2024	Corresponding 3 months ended in previous year on 31/12/2023	Year to date figures for Current period ended 31/12/2024	Year to date figures for Previous period ended 31/12/2023	Previous Year ended on 31/03/2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Segment Revenue</b>						
	Pharma Unit	1,204.77	182.20	179.12	2,126.60	1,271.71	2,786.79
	Chemicals Division	214.75	59.06	324.03	378.52	1,211.55	1,216.74
	<b>Gross Turnover</b>	<b>1,419.52</b>	<b>241.26</b>	<b>503.15</b>	<b>2,505.12</b>	<b>2,483.26</b>	<b>4,003.53</b>
2	<b>Segment Results</b>						
	Pharma Unit	-2.34	-7.02	-4.14	-7.40	-22.07	1.07
	Chemicals Division	25.41	11.20	15.41	58.30	82.87	88.56
	<b>Total Segment Profit Before Tax</b>	<b>23.07</b>	<b>4.18</b>	<b>11.27</b>	<b>50.90</b>	<b>60.80</b>	<b>89.63</b>
	Interest Income	0.06	0.00	0.07	0.11	0.13	0.85
	Interest Expenses	0.97	0.90	0.00	2.78	1.88	3.95
	Other Unallocable Income net of Expenditure						
	<b>Profit Before Tax</b>	<b>22.16</b>	<b>3.28</b>	<b>11.33</b>	<b>48.23</b>	<b>59.05</b>	<b>86.53</b>
3	<b>Capital Employed</b>						
	<b>Segment Assets (A)</b>						
	Pharma Division	3,040.03	1,994.49	1,993.01	3,040.03	1,993.01	2,347.94
	Chemicals Division	1,478.95	2,111.29	2,251.55	1,478.95	2,251.55	2,360.33
	<b>Total (A)</b>	<b>4,518.98</b>	<b>4,105.77</b>	<b>4,244.56</b>	<b>4,518.98</b>	<b>4,244.56</b>	<b>4,708.27</b>
	<b>Segment Liabilities (B)</b>						
	Pharma Division	2,483.46	1,422.05	1,658.78	2,483.46	1,658.78	1,976.69
	Chemicals Division	179.41	868.56	806.80	179.41	806.80	911.30
	<b>Total (B)</b>	<b>2,662.88</b>	<b>2,290.60</b>	<b>2,465.58</b>	<b>2,662.88</b>	<b>2,465.58</b>	<b>2,887.99</b>
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>						
	Pharma Division	556.57	572.44	334.23	556.57	334.23	371.25
	Chemicals Division	1,299.54	1,242.73	1,444.75	1,299.54	1,444.75	1,449.03
	<b>Total Capital Employed (Segment Assets-Segment Liabilities)</b>	<b>1,856.10</b>	<b>1,815.17</b>	<b>1,778.98</b>	<b>1,856.10</b>	<b>1,778.98</b>	<b>1,820.28</b>

Date: 11th February, 2025  
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

Ramesh Shah

Digitally signed by Ramesh Shah  
Date: 2025.02.11 17:16:47 +05'30'

**RAMESH SHAH**  
**CHAIRMAN & MANAGING DIRECTOR**  
(DIN: 00028819)


**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To,  
The Board of Directors  
Biofil Chemicals and Pharmaceuticals Limited  
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("the company") for the quarter ended 31<sup>st</sup> December, 2024 and year to date from 01<sup>st</sup> April, 2024 to 31<sup>st</sup> December, 2024 attached herewith. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), in compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be



aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MAHESHWARI & GUPTA**  
Chartered Accountants  
FRN: 006179C



**CA. SUNIL MAHESHWARI**  
Partner  
M. No. 403346

Place: Indore  
Date: 11/02/2025  
UDIN: 25403346BMMIIE01075